Published in Virus Weekly, August 8th, 2000
"Amprenavir is a potent competitive inhibitor of HIV-1 protease and a relatively weak inhibitor of HIV-2 protease. Inhibition of the HIV-1 protease enzyme results in immature and noninfectious viral particles," said H.B. Fung and colleagues, Bronx Veterans Administration Medical Center, New York ("Amprenavir: A new human immunodeficiency virus type 1 protease inhibitor," Clinical Therapeutics, 2000;22(5):549-572).
According to the researchers,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly